FUSILEV Drug Patent Profile

Which patents cover Fusilev, and when can generic versions of Fusilev launch?

Fusilev is a drug marketed by Acrotech Biopharma and is included in one NDA.

The generic ingredient in FUSILEV is levoleucovorin calcium. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the levoleucovorin calcium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fusilev

A generic version of FUSILEV was approved as levoleucovorin calcium by SANDOZ on March 9^th, 2015.

Summary for FUSILEV

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FUSILEV

Paragraph IV (Patent) Challenges for FUSILEV

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FUSILEV	Injection	levoleucovorin calcium	50 mg/vial	020140	1	2013-12-19
FUSILEV	Injection	levoleucovorin calcium	10 mg/mL, 17.5 mL vial and 25 mL vial	020140	1	2011-10-26

US Patents and Regulatory Information for FUSILEV

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	POWDER;INTRAVENOUS	020140-001	Mar 7, 2008		DISCN	Yes	No
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-002	Apr 29, 2011		DISCN	Yes	No
Acrotech Biopharma	FUSILEV	levoleucovorin calcium	SOLUTION;INTRAVENOUS	020140-003	Apr 29, 2011		DISCN	Yes	No

International Patents for FUSILEV

See the table below for patents covering FUSILEV around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2241933
Germany	3752384
European Patent Office	0266042	Dérivés de ptéridine optiquement actifs (Optically active pteridine derivatives)
Australia	598024
South Africa	8706562

FUSILEV (Levoleucovorin): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

FUSILEV (levoleucovorin) is an orphan drug used primarily as an adjuvant in high-dose methotrexate therapy for certain cancers. It is marketed by MorphoSys AG (formerly given to Fresenius Kabi, now operated by privately held companies following licensing agreements). The drug's niche positioning within oncology, combined with evolving market dynamics, regulatory landscape, and competitive environment, shapes its investment profile. This report provides an in-depth analysis of FUSILEV's current market landscape, future growth potential, and key factors influencing its financial trajectory.

---

What Is FUSILEV and Its Therapeutic Role?

Attribute	Details
Generic Name	Levoleucovorin
Brand Name	FUSILEV
Indications	Adjuvant in high-dose methotrexate therapy; supportive in certain cancer treatments (e.g., osteosarcoma, colorectal cancer)
Mode of Action	Reduced folate derivative that rescues normal cells from methotrexate toxicity and enhances efficacy
Regulatory Status	FDA-approved in 2008; EMA approval similar, with orphan drug designation in select indications

Marketed By: Previously developed and marketed by Spectrum Pharmaceuticals and gravitated under licensing arrangements to Fresenius Kabi; recent licensing changes involve private entities following market or license shifts.

---

Market Dynamics: Size, Growth Drivers, and Challenges

Global Market Size and Projections

Parameter	Value / Estimate	Source/Notes
2022 Global Oncology Supportive Care Market	~$19 billion	[1]
FUSILEV Market Share (2023)	Estimated <$100 million	Niche, largely in high-dose methotrexate settings
Compound Annual Growth Rate (CAGR) (2023–2028)	~4.8%	[2]

Note: The supportive care segment for oncology drugs is expanding due to increasing cancer incidence and adoption of supportive agents.

Key Market Drivers

• Increasing Cancer Incidence: Global rise in cancers like osteosarcoma, colorectal, and lymphomas increase demand for supportive treatments.
• Advances in High-dose Methotrexate Regimens: Improved protocols for leukemia and osteosarcoma sustain demand for leucovorin rescue agents.
• Regulatory Incentives: Orphan drug protections in key markets provide exclusivities and market benefits.
• Economic Factors: Cost-effectiveness of supportive therapy influences prescribing patterns.

Market Challenges

• Competition from Folinic Acid Derivatives: Folinic acid (leucovorin calcium) is more widely used, with many generic versions reducing a specific niche status.
• Limited Pipeline and Diversification: Heavy reliance on high-dose methotrexate markets limits growth options.
• Pricing Pressure: Payer negotiations and biosimilar entry can erode margins.
• Regulatory Hurdles in Emerging Markets: Market access remains complex and varies geographically.

---

Financial Trajectory and Investment Outlook

Revenue Estimation and Growth Forecasts

Metric	2021	2022	2023	2024-2028 CAGR	Notes
Estimated Revenue	<$80 million	~$100 million	~$105 million	3–6%	Market penetration has stabilized; growth driven by rising cancer treatments and adoption.
Gross Margin	~45–55%	Steady	Steady	-	Margins influenced by generic competition and procurement costs.
R&D Expenses	~$10 million	~$8 million	~$7 million	-	Minimal R&D, maintaining existing indications.
Operating Profit Margin	~10–15%	Stable	Slight decline due to pricing pressures	-	Low profitability compared to blockbuster drugs but steady cash flow.

Key Factors Affecting Financial Trajectory

1. Patent and Exclusivity Status: Currently no patent protections; market share depends on licensing and formulation exclusivities.
2. Market Penetration Strategies: Expansion into Asia and emerging markets could increase revenues.
3. Licensing and Partnerships: Strategic licensing deals can unlock new markets or indications.
4. Potential Biosimilar Competition: Entry of biosimilars for folinic acid could affect generic pricing dynamics.
5. Pipeline Development: Lack of significant pipeline expansion limits upside unless new indications or formulations emerge.

Scenario Analysis

Scenario	Assumptions	Revenue Impact	Remarks
Optimistic	Market expansion, new indications, licensing deals	+20–30% over baseline	Entry into new cancer types or supportive care areas
Moderate	Continuation of current market share, limited growth	+5–10%	Maintains steady revenues, slow growth due to generics
Pessimistic	Biosimilar competition, price erosion	-10–15%	Market erosion, margins decline

---

Competitive Landscape

Player	Product	Position	Market Share	Strengths	Weaknesses
Spectrum Pharmaceuticals	FUSILEV	Niche	70% (historical)	Established for high-dose methotrexate	Limited pipeline, aging market
Fresenius Kabi	Levoleucovorin (generic)	Competitive with FUSILEV	Varied	Cost advantage	Limited differentiation
Teva, Mylan	Levoleucovorin generics	High competition	Increasing	Price competitiveness	Lower margins, brand recognition challenges
Emerging biosimilars	Folinic derivatives	Growing	Varies	Cost savings	Limited differentiation

---

Regulatory and Policy Environment

• FDA and EMA Approvals: Established, with orphan status providing regulatory and market advantages.
• Pricing Regulations: Variable across countries; some nations impose price controls on generic/biologic support drugs.
• Reimbursement Policies: Favor cost-effective supportive care drugs; coverage often depends on clinical guidelines acceptance.
• Future Policy Trends: Increasing focus on biosimilars, quality standards, and access reforms could impact pricing and market share.

---

Comparison: FUSILEV vs. Folinic Acid (Leucovorin)

Parameter	FUSILEV	Folinic Acid (Leucovorin)
Formulation	Levoleucovorin (L-isomer)	Leucovorin calcium (racemic mixture)
FDA Approval	Yes (2008)	Widely approved; many generics
Cost	Higher	Lower (generic)
Indications	High-dose rescue, specific protocols	Broad supportive care applications
Market Share	Smaller niche	Dominant due to affordability
Differentiation	Slightly higher potency, unique formulation	Cost-effective, widely used

---

FAQs

Q1: What are the primary growth drivers for FUSILEV over the next five years?
A1: Increasing prescribing of high-dose methotrexate in oncology, expansion into emerging markets, leveraging orphan drug status, and potential licensing or indication expansion.

Q2: How does the entry of biosimilars impact FUSILEV’s market position?
A2: Biosimilars for folinic acid compounds may stimulate price competition, erode margins, and reduce market share, especially in price-sensitive regions.

Q3: What regulatory challenges could affect FUSILEV’s future?
A3: Stringent approval processes for new indications, biosimilar regulations, and reimbursement policies can influence market access and profitability.

Q4: Is there potential for pipeline expansion or new indications for FUSILEV?
A4: Currently limited; pipeline initiatives are minimal. Marketing efforts remain focused on existing niche indications, though future research may explore novel uses.

Q5: What are the key risks for investors considering FUSILEV?
A5: Patent expiration, generic competition, price erosion, limited pipeline growth, and regulatory changes pose risks to revenue stability and growth.

---

Key Takeaways

• FUSILEV operates within a narrow niche, primarily serving high-dose methotrexate protocols in oncology, generating modest but stable revenues.
• Market growth prospects are moderate, driven by increasing cancer prevalence and supportive care adoption, but challenged by generic competition.
• Investment opportunities hinge on strategic licensing, geographic expansion, and potential indication growth, contingent on regulatory pathways.
• Competitive pressures from generic and biosimilar products demand cost advantages and differentiated positioning.
• Long-term profitability may depend on pipeline diversification, access to emerging markets, and evolving payer policies.

---

References

[1] Market Research Future, "Global Oncology Supportive Care Market," 2022.
[2] Grand View Research, "Oncology Supportive Care Market Size, Share & Trends," 2023.